AT 899
Alternative Names: AT-899Latest Information Update: 28 Jun 2024
At a glance
- Originator Atea Pharmaceuticals
- Class Antivirals; Nucleosides
- Mechanism of Action DNA-directed RNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (Parenteral)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (PO, Liquid)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in USA (PO, Tablet)